Article Information
History
- May 28, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Maria Luisa Faquetti1,
- Géraldine Frey1,
- Dominik Stämpfli1,2,
- Stefan Weiler1 and
- Andrea M. Burden1,3,*
- 1Pharmacoepidemiology group, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
- 2Hospital Pharmacy, Kantonsspital Baden, Baden, Switzerland
- 3Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
- ↵*CORRESPONDENCE TO:
Prof. Dr Andrea M. Burden, Institute for Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, HCI H 407 Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland., E-mail address: andrea.burden{at}pharma.ethz.ch
AUTHORS INFORMATION: Maria Luisa Faquetti E-mail address: maria.faquetti{at}pharma.ethz.ch, Géraldine Frey E-mail address: freyge{at}student.ethz.ch, Dominik Stämpfli E-mail address: dominik.staempfli{at}pharma.ethz.ch, Stefan Weiler E-mail address: stefan.weiler{at}pharma.ethz.ch
Posted May 28, 2023.
Examining inappropriate medication in UK primary care for type 2 diabetes patients with polypharmacy
